Mazdutide vs Tirzepatide

Mazdutide wins for: Mechanistically favoring fat over lean mass loss, more robust hepatic fat clearance, slightly better preservation of base energy expenditure, and a side-effect profile users find cleaner at intermediate doses. Mazdutide is especially attractive for users monitoring liver health or wanting to bias weight loss away from lean mass.

Tirzepatide wins for: Sheer raw potency in appetite suppression and speed of significant weight reduction. It remains the gold standard for maximal, straightforward scale loss, with more extensive multi-year literature and the broadest range of titratable dosing. GIP agonist synergy makes it exceptionally powerful for glycemic control and blunting postprandial spikes, and sourcing is significantly easier due to higher compound availability and more documented protocols.

Pick Mazdutide if:

• Recomp protocols prioritize fat over lean mass loss and hepatic fat clearance is a focus.
• Lab subjects with elevated liver enzymes or fatty liver from AAS, bulking, or alcohol history are being studied.
• Users running sub-maximal doses who want energy levels less impacted than with semaglutide/tirzepatide.
• Research protocols need a newer, cleaner-appearing GI side-effect profile at equivalent weight loss targets.
• Study objectives include examining dual GLP-1/glucagon effects on body composition.

Pick Tirzepatide if:

• Protocols demand the absolute maximum in pharmacologic weight/fat loss within a fixed time frame.
• Appetite suppression (vs. energy expenditure modulation) is the overwhelming priority.
• Lean mass preservation is managed aggressively by paired hormone and nutrition interventions.
• Compound availability, protocol documentation, and titration data are research priorities.
• Glycemic control and postprandial glucose reduction are explicit targets in the study design.